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Abstract 
 
Skaug MA, Størmer FC, Saugstad OD. Ochratoxin A: a naturally occurring 
mycotoxin found in human milk samples from Norway. 
 
The presence of ochratoxin A (OA) in human milk samples from different regions in 
Norway has been investigated in order to determine the level of infant exposure to 
OA from human milk. OA was found in 38 (33%) of 115 human milk samples (range 
10-130 ng/l). Two to 26 % of the samples contained more than 40 ng/l OA, which 
will cause a daily intake of OA from human milk exceeding the suggested tolerable 
dose of 5 ng/kg bw. Significant regional differences were found.   
 
Human milk, ochratoxin A, mycotoxin 
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Mycotoxins, such as aflatoxins and ochratoxins are secondary metabolites produced 
by moulds. Ochratoxin A (OA) is produced by Aspergillus and Penicillium species 
growing on cereals and other plant substrates, and is frequently found as a 
contaminant in animal feed and in human food in temperate areas (1, 2).  
 
Humans are exposed to OA by consumption of food which has been directly 
contaminated through growth of fungi, and by food products derived from exposed 
animals. In addition, probably also by inhalation of spores containing mycotoxins (3, 
4). Spores from P. verrucosum, the major ochratoxin producer in crops in the colder 
climatic zones, were shown to contain both OA and citrinin (5), another mycotoxin 
produced by this common mould. Inhalation of spores should consequently be an 
exposure route taken into consideration. 
 
Seasonal fluctuations in OA levels in cereals are reflected by OA levels in humans 
and in animals (2). In general the growth of mould, and the production of mycotoxins 
in the crop depend strongly on environmental conditions such as moisture and 
temperature, and is generally increased in wet summers.  
 
OA has been shown to be nephrotoxic, carcinogenic, teratogenic and 
immunosuppressive (6). Acute human intoxication by OA is unlikely to occur at the 
OA levels generally found in foodstuffs, but the long-term effects of continuous low-
dose exposure to OA on human health could be significant. The major target organ of 
OA toxicity is the kidney. The toxin has been strongly suspected of being involved in 
endemic Balkan nephropathy, and of being associated with urinary tract tumours in 
humans (7).  
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A high incidence of OA contamination of human blood in Europe and Canada 
suggests a continuous and widespread human exposure to this toxin, although at low 
levels. Analyses of blood samples from different European countries show OA 
contamination at concentrations from 100 to 14 400 ng/l (8). The concentration level 
of OA in human milk is reported to be roughly   1/10 that in human blood (9).  
 
Different risk assessments of the intake of OA have been performed, and different 
tolerable daily intakes (TDIs) have been suggested (6, 10, 11). The Nordic Working 
Group on Food Toxicology and Risk Evaluation has suggested a maximum TDI of 
OA in humans of 5 ng per kg body weight, based on carcinogenicity studies with OA 
in rats (12).  
 
In human milk samples highest OA concentrations have been found in Sierra Leone, 
where thirty-five per cent of the samples contained OA at levels from 200 to 337 000 
ng/l OA (detection limit: 200 ng/l) (13). In Italy 20 % of milk samples had OA levels 
in the range of 100 to 12 000 ng/l  (14). Lower concentrations were found in samples 
from Germany (17-30 ng/l in 11% of the samples) (15) and Switzerland (5-14 ng/kg 
in 10% of the samples) (16). In a Swedish study 23 of 40 (58 %) human milk 
samples contained OA (range 10-40 ng/l, detection limit 10 ng/l) (9). 
 
Prenatal exposure to OA can occur by transplacental transfer (17). It is reported that 
the OA concentration in fetal serum is twice the maternal one, indicating a possible 
active placental transport (16). The health risk of OA to neonates and infants has not 
yet been evaluated. 
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The purpose of the present work was to determine the occurrence of OA in human 
milk samples from different regions in Norway and to determine the level of infant 
exposure to OA from human milk. 
 
Materials and methods 
 
Reagents 
OA was purchased from Sigma (St Louis, MO, USA). A solution of OA (10 g /ml 
in methanol) was calibrated spectrophotometrically at 333 nm using the value of 
6640 for the extinction coefficient (18). The OA solution was diluted to 10
-8 
M in 
methanol and stored at -20 C.  
Milk samples 
Human milk samples were collected during May-August 1994. One hundred and 
fifteen milk samples were obtained from women living in three different climatic 
regions in Norway: Elverum (south-east inland, n=48), Trondheim (middle coast, 
n=19) and Bodø (north coast, n=48) (Fig. 1). From each mother one sample was 
taken 3-4 days post partum. No additional personal or dietary information was 
obtained from the donors. The milk samples were stored in sterile tubes, and 
immediately frozen at -20 C until extraction and HPLC analysis.  
The study was approved by the regional ethical committee, Norway. 
Extraction and clean-up 
The method described by Breitholtz-Emanuelsson et al (9) was used with slight 
modifications concerning the purification and HPLC-conditions and with another 
confirmation method for OA. A volume of 5 ml methanol, 0.5 ml 1 M HCl, and 5 ml 
chloroform were added to a 2 ml portion of milk. Instead of a self-packed silica gel 
6 
 
 
column in a Pasteur pipette, a commercially available silica gel cartridge (Bond Elut 
Varian) with 500 mg silica was employed for clean-up of the chloroform extract. The 
silica gel was washed with 5 ml chloroform before the chloroform phase from the 
extraction was added. The solvent of the purified extract was evaporated to dryness 
at 40-45 C under a stream of nitrogen. The residue was immediately dissolved in 
300 l of the HPLC mobile phase by means of ultrasonication. Sample extracts were 
filtered through a 0.45 m membrane filter prior to injection onto the HPLC column.  
Chromatography 
The sample extracts were analysed by HPLC ion-pair technique, at an alkaline pH, 
and with fluorescence detection.  The chromatographic system consisted of a Merck 
Hitachi L-6200 A Intelligent Pump, fluorescence detector (Merck Hitachi F-1080), 
interface (Merck Hitachi D-6000), a Rheodyne manual injector, and chromatography 
software (model Hitachi D-6000 HPLC Manager). Separations were carried out on a 
Spherisorb S3ODS2 (C-18) column, 4.6 x 150 mm, with 3 m particles. A 50 l 
aliquot of the sample extract was injected onto the column. The mobile phase 
consisted of 10 mM tetrabutyl ammonium bromide in a methanol-potassium 
phosphate buffer (pH 7.5) mixture (ratio of methanol to potassium phosphate buffer 
was 51:49). In order to elute late peaks from the column, the ratio of methanol to 
potassium buffer was changed to 56: 44 after elution of OA. The determinations 
were performed at 380 nm (excitation wavelength) and 450 nm (emission 
wavelength). Flow rate was 0.8 ml/min. OA standard solutions (70 -1750 ng/l) for 
calibration were prepared every day by dilution of the 10
-8
M OA stock solution with 
HPLC mobile phase. For quantitation, peak heights were measured by a Merck 
Hitachi integrator. The 10
-8
M OA stock solution was added to milk samples for 
recovery experiments and for calculation of the detection limit of the whole 
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procedure. The mean recovery for the whole procedure, calculated from spiked milk 
samples (concentration range 10 - 500 ng/l), was 75 % (64-84, n= 22). The 
quantitation limit for spiked milk samples was 10 ng/l OA.  
Confirmation 
The identity of OA in positive samples was confirmed in two ways:1) As a routine all 
sample extracts shown to contain OA during initial HPLC analysis were analysed in 
duplicate, with a direct spiking of the second aliquot. This was performed by adding 
an amount of a stock solution of OA to the aliquot. The chromatograms of the 
unspiked and the spiked sample extract were then compared.  2) Derivatization of 
OA through methylation of the extracts with subsequent HPLC analysis was also 
used for qualitative confirmation of positive samples (16): A 200 l aliquot of the 
purified sample extract was evaporated to dryness, and the residue was dissolved in 
2.5 ml methanol and 0.1 ml conc. HCl. The mixture was kept overnight at room 
temperature. After evaporating the mixture to dryness, the residue was dissolved in 
200 l mobile phase. 50 l of it was injected onto the HPLC column and analysed 
(disappearance of the OA peak in the chromatogram and appearance of a new peak 
with the same retention time as that of the methyl ester).  
Statistics 
The standard curves used for quantitation were calculated by the least-squares 
method. The coefficient of variation of the peak height of OA at different injections 
of the same standard solution was 3 % (within-day variation). The coefficient of 
variation of the peak height of OA from spiked milk samples was 12 % (between 
days). Fisher's exact test was used to compare the OA levels in the three areas.   
A p value less than 0.05, using a two tailed test, was considered to be statistically 
significant. 
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Results 
 
Thirty-eight of the 115 human milk samples (33%) contained OA in concentrations 
ranging from 10 to 130 ng/l. The incidence and level of OA contamination varied 
significantly between the three regions (Table 1). Lowest incidence and 
contamination level was found in the northernmost area, north of The Arctic Circle 
(p = 0.0005, A versus region B+C, see map, Fig.1). In this area only 7 of 48 samples 
(15%) had detectable levels of OA, and only one sample contained more than 40 
ng/l. Fourteen of the 115 samples (12 %) contained more than 40 ng OA /l. In the 
northernmost area only 1 of 48 samples (2 %) contained more than 40 ng/l, whereas 
5 of 19 samples (26 %) from the middle part of Norway exceeded this value (p = 
0.006).  
 
 
Discussion 
Supposed a 4-kg infant consumes 500 ml of milk per day the milk must contain less 
than 40 ng OA per l to prevent a daily intake exceeding the suggested TDI of 5 ng/kg 
bw. The present investigation demonstrates that in Norway 2 - 26 % of the infants 
were exposed to milk contaminated with OA at levels that exceed the TDI. 
Significant individual and regional differences in OA levels in the milk were found. 
In the east and middle part of Norway 42 - 58 % of the human milk samples 
contained more than 10 ng/l. Our findings suggest that OA contamination may be a 
potential health problem. Infants are generally more susceptible to exposures to 
environmental toxins than adults, and may be more vulnerable to their effects. Short-
term adverse effects from OA have not been documented in humans at the 
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concentrations known to be present in human milk. However, because of the 
continuous intake and the long elimination half-life (35 days in adult humans) (19) 
the infant may build up high concentrations of the toxin over time. Risk assessments 
that have been carried out for OA do not differentiate between risk to children and 
risk to adults. Further investigations are needed regarding the potential long-term 
health effects of OA intake in the contamination range found in this work. 
 
The prevalence of OA contamination in east- and middle-part of Norway was 
approximately the same as reported in the Swedish study (9), but the mean values 
were higher in the Norwegian samples. The prevalence of OA in human milk in 
Sweden and in Norway is higher than reported from Switzerland (16) and Germany 
(15). The results may indicate that the average exposure to OA of the population in 
some regions of Norway is higher than in Sweden, Germany and Switzerland.  
The geographical variations in the level of OA contamination of the milk seen in this 
study may be due to differences in dietary habits, and may also be due to regional 
differences in inhalation exposure to fungal spores. In the northern part of Norway 
there was a significant lower incidence and level of OA contamination of the milk. 
There are minor farming activities (grain processing, hay handling etc.)  in the 
northern areas, which might reduce the exposure to airborne fungal spores. To 
evaluate the regional differences in OA levels in human milk found in this study, 
more data is needed regarding consumption data and OA levels in foodstuffs in 
Norway. 
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Tab. 1: Occurrence of ochratoxin A in human milk samples from Norway 
Detection limit 10 ng/l ochratoxin A 
 
 
 Concentration 
of ochratoxin A, ng/l 
No of samples 
  
Region Mean 
(Range) 
not detected 10-40 ng/l > 40 ng/l 
Bodø (A) 
n=48 
27.4 
(10-56) 
41 6 1 
Trondheim (B) 
n=19 
49.0 
(10-102) 
8 6 5 
Elverum (C) 
n=48 
43.2 
(10-130) 
28 12 8 
 
 
Figure 1: 
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